Hepatology News and Research RSS Feed - Hepatology News and Research

Hepatology is the branch of medicine that incorporates study of liver, gallbladder, biliary tree and pancreas as well as management of their disorders.

Optimal use of combination therapy achieves best treatment outcomes in patients with CHB

Three new studies presented today at the International Liver CongressTM 2014 have helped clarify the optimal use of combination therapy with peginterferon and nucleoside analogues (NUCs) to achieve the best treatment outcomes in patients with chronic hepatitis B (CHB). [More]
New data focuses on different approaches to improve diagnosis and treatment of HCC

New data focuses on different approaches to improve diagnosis and treatment of HCC

Epidemiological, genetic and clinical data presented today at the International Liver CongressTM 2014 are collectively focussed on different approaches designed to improve the diagnosis, staging and treatment of hepatocellular carcinoma (HCC). [More]

Researchers identify new Chinese herbal medicine that inhibits hepatitis C virus activity

Data from a late-breaking abstract presented at the International Liver CongressTM 2014 identifies a new compound, SBEL1, that has the ability to inhibit hepatitis C virus (HCV) activity in cells at several points in the virus' lifecycle. [More]

Obeticholic acid meets primary composite endpoint in Phase III study

Results from an international Phase III study presented today at the International Liver CongressTM 2014 have shown obeticholic acid (OCA) given to patients suffering from Primary Biliary Cirrhosis (PBC) who previously had an inadequate response to, or have been unable to tolerate ursodeoxycholic acid (UDCA), produced meaningful biochemical and clinical improvements. UDCA is the only therapy currently approved to treat PBC. [More]

New data shows that gut microbiota has potential role in development of ALD

Exciting new data presented today at the International Liver Congress- 2014 shows that the gut microbiota has a potential role in the development of alcoholic liver disease (ALD). [More]

UK study finds link between low vitamin D status and non-alcoholic fatty liver disease in British children

A UK study investigating the link between low vitamin D status and non-alcoholic fatty liver disease (NAFLD) in British children has identified a genetic variant associated with the disease's severity. [More]

Adoptive T-cell therapy may help in treating liver cancer, says study

Significant new data presented today at the International Liver Congress- 2014 indicate that liver cancer (Hepatocellular Carcinoma (HCC)) may be treated by adoptive T-cell therapy. [More]
New research provides new hope for liver transplant patients with recurring hepatitis C

New research provides new hope for liver transplant patients with recurring hepatitis C

New research announced at the International Liver CongressTM 2014 today provides new hope for the notoriously difficult-to-treat population of liver transplant patients with recurring hepatitis C (HCV). [More]
EU-funded project aims to find solution to combat hepatitis C epidemic in Egypt

EU-funded project aims to find solution to combat hepatitis C epidemic in Egypt

New ways to differentiate between chronic and self-clearing infections may help towards effective patient management and reduce drug costs. But there are major challenges in implementation. [More]
Viral hepatitis linked to more deaths than HIV across EU countries

Viral hepatitis linked to more deaths than HIV across EU countries

Mortality from viral hepatitis is significantly higher than from HIV/AIDS across EU countries, according to results from The Global Burden of Disease Study 2010 (GBD 2010) which was announced for the first time today at the International Liver CongressTM 2014. [More]

Novel prediction model improves patient outcomes after paracetamol-induced acute liver failure

In the UK paracetamol toxicity is the most common cause of ALF and has a high mortality rate. It is estimated that 150 to 200 deaths and 15 to 20 LTs occur as a result of poisoning each year in England and Wales. [More]
Studies provide evidence to clarify role of NAFLD as independent risk factor for development of CVD

Studies provide evidence to clarify role of NAFLD as independent risk factor for development of CVD

Two new studies presented today at the International Liver CongressTM 2014 have provided more evidence to clarify the role of non-alcoholic fatty liver disease (NAFLD) as an independent risk factor for the development of cardiovascular disease (CVD). [More]

Gilead Sciences announces positive results from LDV/SOF phase 2 studies on HCV infection

Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from two Phase 2 studies evaluating investigational all-oral regimens containing the nucleotide analog polymerase inhibitor sofosbuvir (SOF) for the treatment of chronic hepatitis C virus (HCV) infection. [More]

EASL to present online HCV management recommendations at the ILCTM

The European Association for the Study of the Liver (EASL) will this week be announcing new on-line recommendations on the management of hepatitis C (HCV) at the International Liver Congress- (ILC). [More]

Drinking two or more cups of coffee each day reduces risk of death from liver cirrhosis by 66%

New research reveals that consuming two or more cups of coffee each day reduces the risk of death from liver cirrhosis by 66%, specifically cirrhosis caused by non-viral hepatitis. Findings in Hepatology, a journal published by Wiley on behalf of the American Association for the Study of Liver Diseases, show that tea, fruit juice, and soft drink consumption are not linked to cirrhosis mortality risk. As with previous studies heavy alcohol use was found to increase risk of death from cirrhosis. [More]
Clinigen Group announces acquisition of SAVENE oncology support therapy from SpePharm

Clinigen Group announces acquisition of SAVENE oncology support therapy from SpePharm

Clinigen Group plc ('Clinigen' or the 'Group') the specialty global pharmaceutical company today announces the acquisition of SAVENEĀ® (dexrazoxane) from SpePharm AG, a majority owned affiliate of Norgine B.V. The Financial terms of the acquisition are not being disclosed. [More]
Non-alcoholic steatohepatitis (NASH): an interview with Jean-François Mouney, CEO of Genfit

Non-alcoholic steatohepatitis (NASH): an interview with Jean-François Mouney, CEO of Genfit

The progressive form of Non-Alcoholic Fatty Liver Disease (NAFLD) is Non-Alcoholic Steatohepatitis (NASH), which defines a subgroup of NAFLD where liver steatosis co-exists with cell injury (hepatocyte ballooning) and inflammation with or without fibrosis at histological examination. [More]

Hepatitis C patients with ITPA gene variants exhibit lower risk of relapse after treatment

More than 100 million humans around the world are infected with hepatitis C virus. The infection gives rise to chronic liver inflammation, which may result in reduced liver function, liver cirrhosis and liver cancer. [More]
Two definitions of CMI symptoms should guide research and treatment of Gulf War veterans

Two definitions of CMI symptoms should guide research and treatment of Gulf War veterans

Two existing definitions of chronic multisymptom illness (CMI) -- one by the Centers for Disease Control and Prevention and another from a study of Kansas Gulf War veterans -- should be used by the U.S. Department of Veterans Affairs to guide research and treatment of Gulf War veterans, says a new report from the Institute of Medicine. [More]
Scientist receives AGA-GCF Research Scholar Award for research in gastric, esophageal cancer

Scientist receives AGA-GCF Research Scholar Award for research in gastric, esophageal cancer

The American Gastroenterological Association (AGA) Research Foundation and the Gastric Cancer Foundation (GCF) are pleased to announce that the first AGA-Gastric Cancer Foundation Research Scholar Award in Gastric and Esophageal Cancer will support Mohamed El-Zaatari, PhD, from University of Michigan, as he conducts research into the role of myeloid cells in the transition from chronic inflammation to gastric pre-neoplasia. [More]